ACTRN12620000339954
已完成
4 期
A randomised double-blind trial comparing the effectiveness of anti-androgen medications in trans and gender diverse individuals
概览
- 阶段
- 4 期
- 干预措施
- 未指定
- 疾病 / 适应症
- transgender
- 发起方
- Austin Health
- 入组人数
- 66
- 状态
- 已完成
- 最后更新
- 3年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Transgender individuals newly commencing feminising therapy with anti\-androgen medication
排除标准
- •Androgen deficiency at baseline
- •Planned orchidectomy within 6 months
- •Contraindication to treatment with estradiol, spironolactone or cyproterone (e.g. estrogen sensitive cancer, venous thromboembolic events, hyperkalaemia, severe depression)
结局指标
主要结局
未指定
相似试验
进行中（未招募）
不适用
A randomised, double-blind study comparing the efficacy and safety of 145mg NanoCrystal® fenofibrate, 10mg ezetimibe and their combination in patients with type IIb dyslipidemia and features of the metabolic syndrome. - see protocol page 1Patients with type IIb dyslipidemia and features of the metabolic syndrome.EUCTR2004-002408-13-DEFOURNIER Laboratories Ireland Ltd186
进行中（未招募）
不适用
A randomised, double-blind study comparing the efficacy and safety of 145mg NanoCrystal® fenofibrate, 10mg ezetimibe and their combination in patients with type IIb dyslipidemia and features of the metabolic syndrome. - see protocol page 1Patients with type IIb dyslipidemia and features of the metabolic syndrome.EUCTR2004-002408-13-BEFOURNIER Laboratories Ireland Ltd186
进行中（未招募）
不适用
A randomized, double-blind trial comparing the efficacy and safety of a fixed combination of fenofibrate and metformin vs rosiglitazone in patients with type 2 diabetes mellitus and dyslipidemia - fenofibrate and metformin fixed combination vs rosiglitazonePatients with type 2 diabetes mellitus and dyslipidemiaMedDRA version: 8.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2005-006060-63-FIFOURNIER Laboratories Ireland Ltd690
已完成
3 期
A randomized, double-blind trial comparing the efficacy and safety of a fixed combination of fenofibrate and metformin vs rosiglitazone in patients with type 2 diabetes mellitus and dyslipidemiadiabetes mellitus type 2 and dyslipidaemia10012653NL-OMON30160Fournier Laboratories72
进行中（未招募）
不适用
A randomized, double-blind trial comparing the efficacy and safety of a fixed combination of fenofibrate and metformin vs rosiglitazone in patients with type 2 diabetes mellitus and dyslipidemia - fenofibrate and metformin fixed combination vs rosiglitazoneEUCTR2005-006060-63-DEFOURNIER Laboratories Ireland Ltd690